Sleep Apnoea in the UK: Undiagnosed in 85% of Sufferers

The Silent Epidemic: Sleep Apnoea in the UK

Obstructive Sleep Apnoea (OSA) affects an estimated 4–10% of the UK adult population, approximately 1.5–4 million people. Yet according to the British Lung Foundation, up to 85% of sufferers remain undiagnosed. OSA causes repeated partial or complete collapse of the upper airway during sleep, leading to oxygen desaturation, fragmented sleep, and excessive daytime sleepiness. Untreated moderate-to-severe OSA doubles the risk of cardiovascular events (heart attack, stroke), increases the risk of type 2 diabetes by 30%, is associated with a 2–7 fold increase in road traffic accident risk, and contributes to hypertension, atrial fibrillation, and cognitive decline. It is one of the most underdiagnosed conditions in UK healthcare.

Symptoms: Beyond Snoring

While loud snoring is the most recognised symptom, many OSA sufferers do not snore loudly or do not have a bed partner to observe their sleep. Key symptoms include: excessive daytime sleepiness (falling asleep in passive situations, watching TV, as a passenger, in meetings), unrefreshing sleep despite adequate duration, morning headaches (caused by overnight CO2 retention), nocturia (waking 2+ times per night to urinate, often attributed to prostate issues in men when it is actually caused by OSA), reduced concentration and memory, mood disturbance (irritability, low mood), reduced libido, and witnessed apnoeas (pauses in breathing during sleep lasting 10+ seconds). The Epworth Sleepiness Scale is a validated screening tool, a score above 10 suggests clinically significant daytime sleepiness. Your GP can administer this in under 2 minutes.

Getting Diagnosed: NHS and Private Pathways

NHS diagnosis typically requires a GP referral to a sleep clinic, where you will undergo a home sleep study (polygraphy) or, in complex cases, an in-hospital polysomnography. NHS waiting times for sleep studies range from 4–16 weeks depending on the trust. Private sleep studies are available from £150–300 for home-based testing (providers include Intus Healthcare, ResMed, and private sleep clinics) and £500–1,500 for in-lab polysomnography. The home sleep study involves wearing a portable device overnight that monitors oxygen levels, airflow, respiratory effort, and body position. Results are reported as an Apnoea-Hypopnoea Index (AHI): 5–15 events per hour is mild OSA, 15–30 is moderate, and over 30 is severe. Treatment recommendations depend on the AHI and symptom severity.

CPAP Treatment: The Gold Standard

Continuous Positive Airway Pressure (CPAP) is the first-line treatment for moderate-to-severe OSA. A CPAP machine delivers a continuous stream of pressurised air through a mask worn during sleep, keeping the airway open and preventing apnoeas. On the NHS, CPAP machines and masks are provided free of charge once diagnosed. Modern CPAP machines are quiet (typically 25–30 decibels), auto-adjusting (sensing the required pressure throughout the night), and provide data tracking via smartphone apps. Adherence is the main challenge, approximately 30–50% of patients struggle with CPAP initially. Common issues include mask discomfort, nasal dryness, claustrophobia, and partner disturbance. Most can be resolved with mask fitting appointments, humidifier attachments, and alternative mask styles (nasal pillows, nasal masks, full-face masks).

Alternatives to CPAP

For patients who cannot tolerate CPAP, alternatives include: mandibular advancement devices (MADs), custom-fitted dental appliances that hold the lower jaw forward, enlarging the airway; positional therapy (if OSA is predominantly positional, sleeping on your side rather than your back can reduce AHI by 50% or more); weight loss (a 10% reduction in body weight can reduce AHI by approximately 26%); and, in selected cases, surgery. Surgical options include uvulopalatopharyngoplasty (UPPP), tonsillectomy, and newer procedures such as hypoglossal nerve stimulation (Inspire therapy), which was approved by NICE in 2023 for patients with moderate-to-severe OSA who cannot use CPAP. Inspire therapy involves an implanted device that stimulates the tongue muscle to keep the airway open during sleep.

The Impact of Treatment on Quality of Life

Effective OSA treatment produces improvements that patients consistently describe as life-changing. Daytime sleepiness typically resolves within 1–2 weeks of consistent CPAP use. Blood pressure reduction of 3–5 mmHg (equivalent to adding a blood pressure medication) occurs within the first month. Cardiovascular risk reduction of 40–64% over 5 years is documented in patients with good CPAP adherence. Cognitive function, particularly memory, concentration, and processing speed, improves measurably within weeks. Partners report improved sleep quality, reduced anxiety about witnessed apnoeas, and improved relationship satisfaction. The economic impact is also significant: treated OSA patients have 50% fewer road traffic accidents and significantly reduced workplace absenteeism.